Recent changes
Jump to navigation
Jump to search
Track the most recent changes to the wiki on this page.
List of abbreviations:
- N
- This edit created a new page (also see list of new pages)
- m
- This is a minor edit
- b
- This edit was performed by a bot
- (±123)
- The page size changed by this number of bytes
31 May 2024
|
m 23:35 | Non-degenerate nucleotides per response element 2 changes history +1 [Marshallsumter (2×)] | |||
m |
|
23:35 (cur | prev) 0 Marshallsumter talk contribs (→Averages per Orders) | |||
m |
|
23:18 (cur | prev) +1 Marshallsumter talk contribs (→Averages per Orders) |
30 May 2024
|
m 23:53 | Non-degenerate nucleotides per response element 2 changes history −52 [Marshallsumter (2×)] | |||
m |
|
23:53 (cur | prev) +2 Marshallsumter talk contribs (→Averages per Orders) | |||
m |
|
06:03 (cur | prev) −54 Marshallsumter talk contribs (→Tabulation of counts) |
28 May 2024
m 07:35 | Non-degenerate nucleotides per response element diffhist 0 Marshallsumter talk contribs (→Tabulation of counts) |
27 May 2024
|
N 23:47 | Template:JR 2 changes history +44 [Jonathan Reyes (2×)] | |||
|
23:47 (cur | prev) −25 Jonathan Reyes talk contribs | ||||
N |
|
22:59 (cur | prev) +69 Jonathan Reyes talk contribs (Created page with "Jonathan Reyes, M.D.[jona3098reyes@gmail.com]") |
N 23:42 | Evinacumab-dgnb diffhist +627 Jonathan Reyes talk contribs (Created page with "{{DrugProjectFormSinglePage |authorTag={{JR}} |genericName=evinacumab-dgnb |aOrAn=an |drugClass=angiopoietin-like 3 (ANGPTL3) inhibitor |indicationType=treatment |indication=Evanicumab-dgnb is an angiopoietin-like 3 (ANGPTL3) inhibitor that is FDA approved for the treatment of an adjunct to other low-density lipoproteincholesterol (LDL-C) lowering therapies for the treatment of adult and pediatric patients, aged 5 years and older, with homozygous familial hypercholestero...") |
26 May 2024
m 20:05 | Non-degenerate nucleotides per response element diffhist −50 Marshallsumter talk contribs (→Tabulation of counts) |